Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Diagnostics
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) treatment is evolving with the advent of targeted therapies.
• Identifying specific molecular targets is key to improving patient outcomes in NSCLC.
• The National Comprehensive Cancer Network (NCCN) Guidelines provide recommendations for NSCLC diagnosis and treatment.

Purpose of the Study:

• To summarize the updated NCCN Guidelines for NSCLC molecular testing.
• To highlight the importance of molecular testing for guiding targeted therapy selection.
• To inform clinicians about newly approved targeted therapies and their indications.

Main Methods:

• Review of the 2018 NCCN Guidelines for NSCLC.
• Identification of recommended molecular targets for NSCLC.
• Summary of approved targeted therapies and their corresponding targets.

Main Results:

• Molecular testing is recommended for initial NSCLC diagnosis.
• Approved targeted therapies exist for EGFR mutations, ALK and ROS1 gene rearrangements, and BRAF mutations.
• New first-line therapies like osimertinib (EGFR inhibitor) and alectinib (ALK inhibitor) are incorporated into the 2018 guidelines.

Conclusions:

• Molecular testing is essential for personalized NSCLC treatment.
• Targeted therapies offer improved outcomes for NSCLC patients with specific molecular alterations.
• The NCCN Guidelines reflect the growing landscape of actionable targets and therapies in NSCLC.